drugset / Trial / NCT05594043
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety and establish a preliminary recommended Phase 2 dose (RP2D) of MK-6598 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adult participants with advanced or metastatic solid tumors.
Timeline
- Start
- 2022-12-21
- Primary completion
- 2025-05-21
- Completion
- 2025-05-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-6598 | Unknown | 50 mg | Oral |
| Subject | MK-6598 | Unknown | 250 mg | Oral |
| Subject | MK-6598 | Unknown | 500 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
Indications
No indication recorded.